Literature DB >> 11575456

IL-5 and TNF-alpha participate in recruitment of eosinophils to intestinal mucosa in ulcerative colitis.

M Lampinen1, M Carlson, P Sangfelt, Y Taha, M Thörn, L Lööf, Y Raab, P Venge.   

Abstract

There is an increased influx of activated eosinophils to the intestinal mucosa in active ulcerative colitis, and an increased release of eosinophil-derived proteins, such as ECP, has also been observed. These findings indicate that eosinophils may contribute to tissue damage and intestinal inflammation in this disease. The relative importance of different chemotactic factors and the impact of steroid treatment on their effect in active ulcerative colitis are not known. We measured the eosinophil chemotactic activity in perfusion fluids from 11 patients with ulcerative colitis before and after steroid treatment and from 7 control patients. The effect of neutralizing antibodies to IL-5 and -8, RANTES, eotaxin, MCP-3, TNF-alpha, GM-CSF was investigated. The chemotactic activity was higher in perfusion fluids from patients than from controls (P = 0.0043). Anti-IL-5 (P = 0.005) and -TNF-alpha (P = 0.017) inhibited the activity in perfusion fluids obtained before treatment. Steroid treatment prevented the effect of all antibodies but had no significant effect on the chemotactic activity. The chemotactic activity correlated with the levels of eosinophil granule proteins in the perfusion fluids. In conclusion, in ulcerative colitis, eosinophils are attracted to the intestinal tissue by chemotactic factors, of which IL-5 and TNF-alpha may be the most prominent steroid-sensitive ones. The steroid-insensitive chemotactic activities remain unidentified.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11575456     DOI: 10.1023/a:1010659803912

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  28 in total

1.  Cytokines induce selective granulocyte chemotactic responses.

Authors:  D B Bittleman; R A Erger; T B Casale
Journal:  Inflamm Res       Date:  1996-02       Impact factor: 4.575

2.  Priming and induction of eosinophil trafficking in guinea-pig cutaneous inflammation by tumour necrosis factor alpha.

Authors:  D M Macari; M M Teixeira; T Ansari; P K Jeffery; P G Hellewell
Journal:  Br J Pharmacol       Date:  1998-11       Impact factor: 8.739

3.  Identification of IL-5 and RANTES as the major eosinophil chemoattractants in the asthmatic lung.

Authors:  J Venge; M Lampinen; L Håkansson; S Rak; P Venge
Journal:  J Allergy Clin Immunol       Date:  1996-05       Impact factor: 10.793

4.  A 48-well micro chemotaxis assembly for rapid and accurate measurement of leukocyte migration.

Authors:  W Falk; R H Goodwin; E J Leonard
Journal:  J Immunol Methods       Date:  1980       Impact factor: 2.303

5.  Increased intraluminal release of eosinophil granule proteins EPO, ECP, EPX, and cytokines in ulcerative colitis and proctitis in segmental perfusion.

Authors:  M Carlson; Y Raab; C Peterson; R Hällgren; P Venge
Journal:  Am J Gastroenterol       Date:  1999-07       Impact factor: 10.864

6.  Activated eosinophils and interleukin 5 expression in early recurrence of Crohn's disease.

Authors:  S Dubucquoi; A Janin; O Klein; P Desreumaux; P Quandalle; A Cortot; M Capron; J F Colombel
Journal:  Gut       Date:  1995-08       Impact factor: 23.059

7.  Mast cells are an important cellular source of tumour necrosis factor alpha in human intestinal tissue.

Authors:  S C Bischoff; A Lorentz; S Schwengberg; G Weier; R Raab; M P Manns
Journal:  Gut       Date:  1999-05       Impact factor: 23.059

8.  Differential in situ expression of the genes encoding the chemokines MCP-1 and RANTES in human inflammatory bowel disease.

Authors:  L Mazzucchelli; C Hauser; K Zgraggen; H E Wagner; M W Hess; J A Laissue; C Mueller
Journal:  J Pathol       Date:  1996-02       Impact factor: 7.996

9.  Priming of eosinophil and neutrophil migratory responses by interleukin 3 and interleukin 5.

Authors:  L Håkansson; P Venge
Journal:  APMIS       Date:  1994-04       Impact factor: 3.205

10.  Human monocyte chemotactic proteins-2 and 3 (MCP-2 and MCP-3) attract human eosinophils and desensitize the chemotactic responses towards RANTES.

Authors:  N Noso; P Proost; J Van Damme; J M Schröder
Journal:  Biochem Biophys Res Commun       Date:  1994-05-16       Impact factor: 3.575

View more
  26 in total

1.  Inflammatory Bowel Disease: Future Therapies.

Authors:  Sander J.H. Van Deventer
Journal:  Curr Treat Options Gastroenterol       Date:  2002-06

2.  Exacerbation of oxazolone colitis by infection with the helminth Hymenolepis diminuta: involvement of IL-5 and eosinophils.

Authors:  Arthur Wang; Maria Fernando; Gabriella Leung; Van Phan; David Smyth; Derek M McKay
Journal:  Am J Pathol       Date:  2010-10-29       Impact factor: 4.307

3.  The role of eosinophils in inflammatory bowel disease.

Authors:  S Al-Haddad; R H Riddell
Journal:  Gut       Date:  2005-12       Impact factor: 23.059

4.  Eosinophil granulocytes are activated during the remission phase of ulcerative colitis.

Authors:  M Lampinen; A Rönnblom; K Amin; G Kristjansson; F Rorsman; P Sangfelt; B Säfsten; M Wagner; A Wanders; O Winqvist; M Carlson
Journal:  Gut       Date:  2005-05-10       Impact factor: 23.059

5.  Down-regulation of interferon-gamma parallels clinical response to selective leukocyte apheresis in patients with inflammatory bowel disease: a 12-month follow-up study.

Authors:  V Muratov; J Lundahl; A K Ulfgren; K Elvin; I Fehrman; N Ahlborg; A Ost; N Hittel; A Saniabadi; R Löfberg
Journal:  Int J Colorectal Dis       Date:  2006-03-15       Impact factor: 2.571

6.  A pilot open-labeled prospective randomized study between weekly and intensive treatment of granulocyte and monocyte adsorption apheresis for active ulcerative colitis.

Authors:  Atsushi Sakuraba; Toshiro Sato; Makoto Naganuma; Yuichi Morohoshi; Katsuyoshi Matsuoka; Nagamu Inoue; Hiromasa Takaishi; Haruhiko Ogata; Yasushi Iwao; Toshifumi Hibi
Journal:  J Gastroenterol       Date:  2008-02-24       Impact factor: 7.527

7.  CD14+CD33+ myeloid cell-CCL11-eosinophil signature in ulcerative colitis.

Authors:  Maria Lampinen; Amanda Waddell; Richard Ahrens; Marie Carlson; Simon P Hogan
Journal:  J Leukoc Biol       Date:  2013-07-31       Impact factor: 4.962

8.  Colonic hypereosinophilia in ulcerative colitis may help to predict the failure of steroid therapy.

Authors:  Giuseppe Leoncini; Vincenzo Villanacci; Maria Grazia Marin; Valentina Crisafulli; Moris Cadei; Elisabetta Antonelli; Claudio Leoci; Gabrio Bassotti
Journal:  Tech Coloproctol       Date:  2018-12-10       Impact factor: 3.781

9.  Effects of adacolumn selective leukocytapheresis on plasma cytokines during active disease in patients with active ulcerative colitis.

Authors:  Hiroyuki Hanai; Takayuki Iida; Masami Yamada; Yoshihiko Sato; Ken Takeuchi; Tatsuo Tanaka; Kenji Kondo; Masataka Kikuyama; Yasuhiko Maruyama; Yasushi Iwaoka; Akiko Nakamura; Kazuhisa Hirayama; Abby R Saniabadi; Fumitoshi Watanabe
Journal:  World J Gastroenterol       Date:  2006-06-07       Impact factor: 5.742

10.  Intestinal macrophage/epithelial cell-derived CCL11/eotaxin-1 mediates eosinophil recruitment and function in pediatric ulcerative colitis.

Authors:  Richard Ahrens; Amanda Waddell; Luqman Seidu; Carine Blanchard; Rebecca Carey; Elizabeth Forbes; Maria Lampinen; Tara Wilson; Elizabeth Cohen; Keith Stringer; Edgar Ballard; Ariel Munitz; Huan Xu; Nancy Lee; James J Lee; Marc E Rothenberg; Lee Denson; Simon P Hogan
Journal:  J Immunol       Date:  2008-11-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.